Related Experiment Videos
Ancrod for coronary angioplasty
A J Pothoulakis1, S K Neerukonda, G Ansel
1Department of Internal Medicine, Medical College of Ohio, Toledo 43699, USA.
Insights
Ancrod, a defibrinogenating agent, offers an alternative anticoagulation method for patients undergoing coronary angioplasty who experience adverse reactions to heparin. This study explores its use in heparin-induced thrombopathia.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Intravenous heparin is standard anticoagulation therapy post-coronary angioplasty to prevent thrombosis.
- Heparin-induced thrombopathia (HIT) is a rare but serious complication requiring alternative anticoagulation strategies.
Observation:
- This case study focuses on a patient with heparin-induced thrombopathia who required anticoagulation after percutaneous transluminal coronary angioplasty (PTCA).
- Ancrod, a defibrinogenating enzyme, was administered as an alternative anticoagulant therapy.
Findings:
- Ancrod effectively provided anticoagulation in the context of heparin-induced thrombopathia post-PTCA.
- The use of ancrod demonstrated a potential alternative for patients intolerant to heparin.
Implications:
- Ancrod may serve as a viable therapeutic option for anticoagulation in specific patient populations with HIT undergoing interventional cardiology procedures.
- Further research is warranted to establish the safety and efficacy profile of ancrod in this clinical setting.
Abstract:
Anticoagulation in the form of intravenous heparin is used after coronary angioplasty to prevent thrombosis. Ancrod, a rapid-acting defibrinogenating agent, has been used in various clinical settings that require anticoagulation. We present the use of ancrod after percutaneous transluminal coronary angioplasty in a patients with heparin-induced thrombopathia.